{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:40:11Z","timestamp":1787586011552,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"\u201cLeading Geese\u201d Research and Development Plan of Zhejiang Province","award":["NO. 2024C03190"],"award-info":[{"award-number":["NO. 2024C03190"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["NO. 82274273"],"award-info":[{"award-number":["NO. 82274273"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02105-7","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:36:14Z","timestamp":1773891374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Superior outcomes with the FABT regimen in haploidentical transplantation for aplastic anemia in patients under 40 years old: a single-center retrospective study"],"prefix":"10.1007","volume":"26","author":[{"given":"Zhengwei","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuechao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonglin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dijiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baodong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"2105_CR1","doi-asserted-by":"crossref","unstructured":"Scheinberg P. Novel therapeutic choices in immune aplastic anemia. F1000Research 9, F1000 Faculty Rev (2020).","DOI":"10.12688\/f1000research.22214.1"},{"key":"2105_CR2","doi-asserted-by":"crossref","unstructured":"A K et al. Guidelines for the diagnosis and management of adult aplastic anaemia: a british society for haematology guideline. Br J Haematol 204, (2024).","DOI":"10.1111\/bjh.19236"},{"key":"2105_CR3","doi-asserted-by":"crossref","unstructured":"X L et al. Comparison of efficacy of eltrombopag combined with immunosuppression in the treatment of severe aplastic anemia and very severe aplastic anemia: real-world data and evidence. Ann Hematol 103, (2024).","DOI":"10.1007\/s00277-024-05910-w"},{"key":"2105_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-06152-6","author":"Z Tan","year":"2025","unstructured":"Tan Z, et al. Hematopoietic stem cell transplantation and immunosuppressive therapy: implications of clonal haematopoiesis. Ann Hematol. 2025. https:\/\/doi.org\/10.1007\/s00277-024-06152-6.","journal-title":"Ann Hematol"},{"key":"2105_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/17474086.2021.1923475","volume":"14","author":"Z-L Xu","year":"2021","unstructured":"Xu Z-L, Huang X-J. Optimizing outcomes for haploidentical hematopoietic stem cell transplantation in severe aplastic anemia with intensive GVHD prophylaxis: a review of current findings. Expert Rev Hematol. 2021;14:449\u201355.","journal-title":"Expert Rev Hematol"},{"key":"2105_CR6","doi-asserted-by":"crossref","unstructured":"R I et al. Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies. Blood Rev 47, (2021).","DOI":"10.1016\/j.blre.2020.100772"},{"key":"2105_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12185-024-03715-1","volume":"119","author":"Y Onishi","year":"2024","unstructured":"Onishi Y. Aplastic anemia: history and recent developments in diagnosis and treatment. Int J Hematol. 2024;119:217\u20139.","journal-title":"Int J Hematol"},{"key":"2105_CR8","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/bjh.17403","volume":"194","author":"P Scheinberg","year":"2021","unstructured":"Scheinberg P. Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries. Br J Haematol. 2021;194:954\u201369.","journal-title":"Br J Haematol"},{"key":"2105_CR9","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41409-020-01169-7","volume":"56","author":"Z-L Xu","year":"2021","unstructured":"Xu Z-L, Huang X-J. Haploidentical stem cell transplantation for aplastic anemia: the current advances and future challenges. Bone Marrow Transpl. 2021;56:779\u201385.","journal-title":"Bone Marrow Transpl"},{"key":"2105_CR10","doi-asserted-by":"crossref","unstructured":"G E et al. Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the european group for blood and marrow transplantation (SAAWP of EBMT). Bone Marrow Transpl 55, (2020).","DOI":"10.1038\/s41409-020-0897-2"},{"key":"2105_CR11","doi-asserted-by":"crossref","unstructured":"K Y et al. Haploidentical peripheral stem cell transplantation for young patients with severe aplastic anemia using post-transplantation cyclophosphamide and methotrexate. Transpl Cell Ther 27, (2021).","DOI":"10.1016\/j.jtct.2021.02.014"},{"key":"2105_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/bmt.2013.224","volume":"49","author":"L Gao","year":"2014","unstructured":"Gao L, et al. Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy. Bone Marrow Transplant. 2014;49:519\u201324.","journal-title":"Bone Marrow Transplant"},{"key":"2105_CR13","unstructured":"Luznik L et al. HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide."},{"key":"2105_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","volume":"13","author":"CG Kanakry","year":"2016","unstructured":"Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13:10\u201324.","journal-title":"Nat Rev Clin Oncol"},{"key":"2105_CR15","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1182\/bloodadvances.2020001729","volume":"4","author":"AE DeZern","year":"2020","unstructured":"DeZern AE, et al. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020;4:1770\u20139.","journal-title":"Blood Adv"},{"key":"2105_CR16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.bbmt.2016.12.628","volume":"23","author":"AE DeZern","year":"2017","unstructured":"DeZern AE, et al. Alternative donor transplantation with high-dose post-transplantation cyclophosphamide for refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2017;23:498\u2013504.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2105_CR17","doi-asserted-by":"crossref","unstructured":"Ae D et al. Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. Lancet Haematol 9, (2022).","DOI":"10.1016\/S2352-3026(22)00206-X"},{"key":"2105_CR18","doi-asserted-by":"crossref","unstructured":"Mh J et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl : J Am Soc Blood Marrow Transpl. 21, (2015).","DOI":"10.1016\/j.bbmt.2014.12.035"},{"key":"2105_CR19","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3324\/haematol.13829","volume":"94","author":"P Scheinberg","year":"2009","unstructured":"Scheinberg P, et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica. 2009;94:348\u201354.","journal-title":"Haematologica"},{"key":"2105_CR20","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/j.bbmt.2020.07.028","volume":"26","author":"V Chinnabhandar","year":"2020","unstructured":"Chinnabhandar V, et al. Addition of thiotepa to total body irradiation and cyclophosphamide conditioning for allogeneic hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2020;26:2068\u201374.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2105_CR21","doi-asserted-by":"publisher","first-page":"e952","DOI":"10.1097\/HS9.0000000000000952","volume":"7","author":"F Saraceni","year":"2023","unstructured":"Saraceni F, et al. Thiotepa-busulfan-fludarabine compared to treosulfan-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with acute myeloid leukemia in remission: a study from the acute leukemia working party of the EBMT. Hemasphere. 2023;7:e952.","journal-title":"Hemasphere"},{"key":"2105_CR22","doi-asserted-by":"crossref","unstructured":"Y L et al. Haploidentical transplantation with modified post-transplantation cyclophosphamide for patients with primary aplastic anemia: a multicenter experience. Transpl Cell Ther 27, (2021).","DOI":"10.1016\/j.jtct.2021.01.018"},{"key":"2105_CR23","doi-asserted-by":"crossref","unstructured":"R A et al. Association between anti-thymocyte globulin exposure and CD4\u2009+\u2009immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol 2, (2015).","DOI":"10.1016\/S2352-3026(15)00045-9"},{"key":"2105_CR24","doi-asserted-by":"publisher","first-page":"332.e1","DOI":"10.1016\/j.jtct.2022.03.018","volume":"28","author":"H Wang","year":"2022","unstructured":"Wang H. Optimal active anti-thymocyte globulin exposure associated with minimum risk of virus reactivation and comparable acute graft-versus-host disease under adult myeloablative haploidentical peripheral blood stem cell transplantation. Transplant Cell Ther. 2022;28:332.e1-332.e10.","journal-title":"Transplant Cell Ther"},{"key":"2105_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2020-139208","volume":"136","author":"A Pradier","year":"2020","unstructured":"Pradier A, et al. Impact of different T cell depletion protocols on immune reconstitution following allogeneic hematopoietic stem cell transplantation. Blood. 2020;136:43\u20134.","journal-title":"Blood"},{"key":"2105_CR26","doi-asserted-by":"crossref","unstructured":"Ad H et al. Post-transplantation cyclophosphamide uniquely restrains alloreactive CD4\u2009+\u2009T-cell proliferation and differentiation after murine MHC-haploidentical hematopoietic cell transplantation. Front Immunol 13, (2022).","DOI":"10.3389\/fimmu.2022.887648"},{"key":"2105_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.796349","volume":"13","author":"AD Hadjis","year":"2022","unstructured":"Hadjis AD, et al. Post-transplantation cyclophosphamide uniquely restrains alloreactive CD4\u2009+\u2009T-cell proliferation and differentiation after murine MHC-haploidentical hematopoietic cell transplantation. Front Immunol. 2022;13:796349.","journal-title":"Front. Immunol."},{"key":"2105_CR28","doi-asserted-by":"crossref","unstructured":"Lp X et al. Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. Br J Haematol 175, (2016).","DOI":"10.1111\/bjh.14225"},{"key":"2105_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0398-y","volume":"10","author":"L-P Xu","year":"2017","unstructured":"Xu L-P, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol. 2017;10:25.","journal-title":"J. Hematol. Oncol."},{"key":"2105_CR30","doi-asserted-by":"crossref","unstructured":"Z W, X, Z., H, Y., D, L., H W. Good outcome of haploidentical hematopoietic SCT as a salvage therapy in children and adolescents with acquired severe aplastic anemia. Bone Marrow Transplant 49, (2014).","DOI":"10.1038\/bmt.2014.187"},{"key":"2105_CR31","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/bmt.2010.213","volume":"46","author":"AE Dezern","year":"2011","unstructured":"Dezern AE, Luznik L, Fuchs EJ, Jones RJ, Brodsky RA. Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia. Bone Marrow Transplant. 2011;46:1012\u20133.","journal-title":"Bone Marrow Transplant"},{"key":"2105_CR32","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.bbmt.2010.05.010","volume":"16","author":"HJ Kang","year":"2010","unstructured":"Kang HJ, et al. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: a phase II prospective multicenter study. Biol Blood Marrow Transplant. 2010;16:1582\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2105_CR33","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.bbmt.2016.04.003","volume":"22","author":"HJ Kang","year":"2016","unstructured":"Kang HJ, et al. Improved outcome of a reduced toxicity-fludarabine, cyclophosphamide, plus antithymocyte globulin conditioning regimen for unrelated donor transplantation in severe aplastic anemia: comparison of 2 multicenter prospective studies. Biol Blood Marrow Transplant. 2016;22:1455\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2105_CR34","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.leukres.2014.01.002","volume":"38","author":"H Kim","year":"2014","unstructured":"Kim H, et al. Allogeneic hematopoietic cell transplantation without total body irradiation from unrelated donor in adult patients with idiopathic aplastic anemia: fludarabine versus cyclophosphamide-ATG. Leuk Res. 2014;38:730\u20136.","journal-title":"Leuk Res"},{"key":"2105_CR35","doi-asserted-by":"publisher","first-page":"1003.e1","DOI":"10.1016\/j.jtct.2021.09.003","volume":"27","author":"RS Mehta","year":"2021","unstructured":"Mehta RS. Bone marrow versus peripheral blood grafts for haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide. Transplant Cell Ther. 2021;27:1003.e1-1003.e13.","journal-title":"Transplant Cell Ther"},{"key":"2105_CR36","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO-24-02119","volume":"43","author":"H Yao","year":"2025","unstructured":"Yao H, et al. Sequential infusion of mesenchymal stem cell for graft-versus-host disease prevention in haploidentical hematopoietic stem cell transplantation: an open-label, multicenter, randomized controlled clinical trial. J Clin Oncol. 2025;43:1997\u20132006.","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02105-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02105-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02105-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:11:30Z","timestamp":1774372290000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02105-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2105"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02105-7","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the Ethics Committee of The First Affiliated Hospital of Zhejiang Chinese Medical University (Approval number: 2024-KLS-631-01). Written informed consent was obtained from all patients and donors prior to treatment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"196"}}